S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:ZGNXZogenix Stock Price, Forecast & News

$24.76
+0.02 (+0.08 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$23.93
Now: $24.76
$25.22
50-Day Range
$23.69
MA: $26.80
$29.36
52-Week Range
$16.65
Now: $24.76
$57.22
Volume1.13 million shs
Average Volume1.08 million shs
Market Capitalization$1.37 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.63
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Read More
Zogenix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.65 million
Book Value$5.54 per share

Profitability

Net Income$-419,500,000.00
Net Margins-8,758.48%

Miscellaneous

Employees90
Market Cap$1.37 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$24.76
+0.02 (+0.08 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

How has Zogenix's stock price been impacted by Coronavirus?

Zogenix's stock was trading at $22.69 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZGNX stock has increased by 9.1% and is now trading at $24.76.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Zogenix?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zogenix
.

When is Zogenix's next earnings date?

Zogenix is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Zogenix
.

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) posted its earnings results on Wednesday, August, 5th. The company reported ($0.96) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.02) by $0.06. The firm earned $1.03 million during the quarter, compared to analyst estimates of $1.10 million. Zogenix had a negative net margin of 8,758.48% and a negative return on equity of 57.75%.
View Zogenix's earnings history
.

What price target have analysts set for ZGNX?

11 equities research analysts have issued 12 month price objectives for Zogenix's stock. Their forecasts range from $27.00 to $78.00. On average, they anticipate Zogenix's share price to reach $55.22 in the next twelve months. This suggests a possible upside of 123.0% from the stock's current price.
View analysts' price targets for Zogenix
.

Has Zogenix been receiving favorable news coverage?

News headlines about ZGNX stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zogenix earned a news impact score of -2.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Zogenix
.

Are investors shorting Zogenix?

Zogenix saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 7,130,000 shares, an increase of 16.3% from the January 31st total of 6,130,000 shares. Based on an average daily volume of 875,700 shares, the short-interest ratio is presently 8.1 days.
View Zogenix's Short Interest
.

Who are some of Zogenix's key competitors?

What other stocks do shareholders of Zogenix own?

Who are Zogenix's key executives?

Zogenix's management team includes the following people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 60)
  • Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 51)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 57)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 55)
  • Mr. Ashish M. Sagrolikar, Exec. VP & Chief Commercial Officer

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Who are Zogenix's major shareholders?

Zogenix's stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (3.86%), Bank of New York Mellon Corp (2.60%), FMR LLC (2.02%), Candriam Luxembourg S.C.A. (1.71%), Cadian Capital Management LP (1.60%) and Emerald Advisers LLC (1.13%). Company insiders that own Zogenix stock include Ashish M Sagrolikar, Cam L Garner, Erle T Mast, Gail M Farfel, James B Breitmeyer, Mark C Wiggins, Michael P Smith, Renee P Tannenbaum, Roger Hawley and Stephen J Farr.
View institutional ownership trends for Zogenix
.

Which major investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, International Biotechnology Trust PLC, Bailard Inc., WINTON GROUP Ltd, Oak Ridge Investments LLC, Premier Asset Management LLC, Ensign Peak Advisors Inc, and GW&K Investment Management LLC. Company insiders that have sold Zogenix company stock in the last year include Gail M Farfel, James B Breitmeyer, Michael P Smith, and Stephen J Farr.
View insider buying and selling activity for Zogenix
.

Which major investors are buying Zogenix stock?

ZGNX stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Cadian Capital Management LP, Bank of New York Mellon Corp, Marshall Wace LLP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Marshall Wace North America L.P., and Federated Hermes Inc.. Company insiders that have bought Zogenix stock in the last two years include Ashish M Sagrolikar, Cam L Garner, and Mark C Wiggins.
View insider buying and selling activity for Zogenix
.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $24.76.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.37 billion and generates $3.65 million in revenue each year. The company earns $-419,500,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis. Zogenix employs 90 workers across the globe.

What is Zogenix's official website?

The official website for Zogenix is www.zogenix.com.

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.